PMID- 25824903
OWN - NLM
STAT- MEDLINE
DCOM- 20160204
LR  - 20150513
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 21
IP  - 6
DP  - 2015 Jun
TI  - Functional differences between antiviral activities of sulfonated and intact 
      intravenous immunoglobulin preparations toward varicella-zoster virus and 
      cytomegalovirus.
PG  - 427-33
LID - S1341-321X(15)00031-8 [pii]
LID - 10.1016/j.jiac.2015.01.012 [doi]
AB  - Intravenous immunoglobulin (IVIG) is used to treat severe viral infection, 
      especially varicella-zoster virus (VZV) and cytomegalovirus (CMV) infections. The 
      neutralization antibody titers of eleven IVIG preparations from four companies 
      were examined using VZV and CMV with and without complement. The neutralizing 
      antibody titers of intact IgG preparations were three to six times higher after 
      addition of complement. The effectiveness of the sulfonated IgG preparation was 
      not enhanced by complement, but desulfonated IgG regained enhanced neutralization 
      activity with complement. Antibody-dependent cellular cytotoxicity (ADCC) toward 
      VZV-infected cells was observed with both intact and sulfonated IVIG and guinea 
      pig splenocytes, but ADCC toward CMV-infected cells was not, although NK cell 
      activity toward cells infected with VZV or CMV was detected by splenocytes. 
      Sulfonated IVIG had no complement-activated neutralization of VZV and CMV but 
      retained ADCC toward VZV with less activity after dilution than with intact IVIG. 
      Because sulfonated IVIG is converted to the intact form after intravenous 
      administration, it would show complement-enhanced neutralization and ADCC 
      activity similar to that of intact IVIG in vivo. In this study we showed the 
      effects of intact and sulfonated IgG on the functional activity of IgG against 
      VZV and CMV.
CI  - Copyright (c) 2015 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Yajima, Misako
AU  - Yajima M
AD  - Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, 
      Japan.
FAU - Shiraki, Atsuko
AU  - Shiraki A
AD  - Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, 
      Japan.
FAU - Daikoku, Tohru
AU  - Daikoku T
AD  - Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, 
      Japan.
FAU - Oyama, Yukari
AU  - Oyama Y
AD  - Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, 
      Japan.
FAU - Yoshida, Yoshihiro
AU  - Yoshida Y
AD  - Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, 
      Japan.
FAU - Shiraki, Kimiyasu
AU  - Shiraki K
AD  - Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, 
      Japan. Electronic address: kshiraki@med.u-toyama.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150219
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antiviral Agents)
RN  - 0 (IgG, sulfonated)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Animals
MH  - Antibodies, Neutralizing/immunology
MH  - Antibodies, Viral/immunology
MH  - Antiviral Agents/*immunology
MH  - Cell Line
MH  - Chickenpox/immunology
MH  - Cytomegalovirus/*immunology
MH  - Cytomegalovirus Infections/immunology
MH  - Guinea Pigs
MH  - Herpesvirus 3, Human/*immunology
MH  - Humans
MH  - Immunoglobulin G/*immunology
MH  - Immunoglobulins, Intravenous/*immunology
MH  - Killer Cells, Natural/immunology
OTO - NOTNLM
OT  - Conformation
OT  - Human cytomegalovirus
OT  - Immunoglobulin
OT  - Sulfonation
OT  - Varicella-zoster virus
EDAT- 2015/04/01 06:00
MHDA- 2016/02/05 06:00
CRDT- 2015/04/01 06:00
PHST- 2014/11/11 00:00 [received]
PHST- 2015/01/07 00:00 [revised]
PHST- 2015/01/20 00:00 [accepted]
PHST- 2015/04/01 06:00 [entrez]
PHST- 2015/04/01 06:00 [pubmed]
PHST- 2016/02/05 06:00 [medline]
AID - S1341-321X(15)00031-8 [pii]
AID - 10.1016/j.jiac.2015.01.012 [doi]
PST - ppublish
SO  - J Infect Chemother. 2015 Jun;21(6):427-33. doi: 10.1016/j.jiac.2015.01.012. Epub 
      2015 Feb 19.